Silver sulfadiazine

Generic Medicine Info
Hypersensitivity. Premature infants or neonates (≤2 months). Pregnancy (near or at term).
Special Precautions
Patient with hypersensitivity to sulfonamide derived medicines, G6PD deficiency. Not recommended for use in very exudative leg or pressure ulcers. Hepatic and renal impairment. Lactation. Monitoring Parameters Perform urinalysis, renal function tests, CBC (patient with extensive burns and on long-term treatment). Monitor serum electrolytes; serum sulfa concentrations (as necessary).
Adverse Reactions
Significant: Fungal or bacterial superinfection including C.difficile-associated diarrhoea (CDAD) and pseudomembranous colitis, leucopenia (prolonged use); delayed eschar separation. Rarely, fungal proliferation. General disorders and administration site conditions: Application site burning. Immune system disorders: Hypersensitivity reactions. Skin and subcutaneous tissue disorders: Pruritus, rash, eczema, contact dermatitis, erythema multiforme, skin discolouration, photosensitivity. Rarely, Argyria (prolonged use/large area of application).
Potentially Fatal: Stevens-Johnson syndrome.
B Silver sulfadiazine is not recommended during near term pregnancy due to the potential risk of neonatal hyperbilirubinaemia and kernicterus.
Drug Interactions
May inactivate enzymatic debriding agents. May alter the effects of oral hypoglycaemic agents and phenytoin (application in large areas).
CIMS Class
Topical Antibiotics
ATC Classification
D06BA01 - silver sulfadiazine ; Belongs to the class of topical sulfonamides used in the treatment of dermatological diseases.
Disclaimer: This information is independently developed by CIMS based on silver sulfadiazine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in